Results 101 to 110 of about 22,161 (218)

Monoaminergic Neuropathology in Alzheimer's disease [PDF]

, 2016
Acknowledgments This work was supported by The Croatian Science Foundation grant. no. IP-2014-09-9730 (“Tau protein hyperphosphorylation, aggregation, and trans-synaptic transfer in Alzheimer’s disease: cerebrospinal fluid analysis and assessment of ...
Bažadona, Danira, Buée, Luc, Delalle, Ivana, Giovanni, Giuseppe Di, Harrington, Charles R., Hof, Patrick R., Jovanov-Milošević, Nataša, Leko, Mirjana Babić, Silva, Rohan de, Wischik, Claude M., Wray, Selina, Šimić, Goran   +11 more
core   +1 more source

Dynamic expression of genes associated with schizophrenia and bipolar disorder across development [PDF]

, 2019
Common genetic variation contributes a substantial proportion of risk for both schizophrenia and bipolar disorder. Furthermore, there is evidence of significant, but not complete, overlap in genetic risk between the two disorders.
Clifton, Nicholas E., Di Florio, Arianna, Hall, Jeremy, Hannon, Eilis, Harwood, Janet C., Holmans, Peter A., O'Donovan, Michael, Owen, Michael J., Pocklington, Andrew J., Thomas, Kerrie L., Walters, James T. R.   +10 more
core   +3 more sources

Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells

OncoImmunology, 2018
Shedding of ADAM10 substrates, like TNFα, MICA or CD30, is reported to affect both anti-tumor immune response and antibody-drug-conjugate (ADC)-based immunotherapy.
Francesca Tosetti, Roberta Venè, Caterina Camodeca, Elisa Nuti, Armando Rossello, Cristina D'Arrigo, Denise Galante, Nicoletta Ferrari, Alessandro Poggi, Maria Raffaella Zocchi   +9 more
doaj   +1 more source

The molecular basis of T cell acute lymphoblastic leukemia [PDF]

, 2012
T cell acute lymphoblastic leukemias (T-ALLs) arise from the malignant transformation of hematopoietic progenitors primed toward T cell development, as result of a multistep oncogenic process involving constitutive activation of NOTCH signaling and ...
Adolfo Ferrando, Bash, Bash, Chen, Condorelli, Dube, Fisch, Hagemeijer, Hebert, Ho, Kelliher, Kikuchi, Larson, Lu, McGuire, McGuire, Nagel, Ntziachristos, Ntziachristos, Ono, Pieter Van Vlierberghe, Royer-Pokora, Rubnitz, van Grotel   +23 more
core   +1 more source

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Journal of Neuroinflammation, 2018
Background The disintegrin metalloproteinase 10 (ADAM10) is the main α-secretase acting in the non-amyloidogenic processing of the amyloid precursor protein.
Aitana Sogorb-Esteve, María-Salud García-Ayllón, Johan Gobom, Jordi Alom, Henrik Zetterberg, Kaj Blennow, Javier Sáez-Valero   +6 more
doaj   +1 more source

Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis [PDF]

, 2017
IgA nephropathy (IgAN) is the most prevalent among primary glomerular diseases worldwide. Although our understanding of IgAN has advanced significantly, its underlying biology and potential drug targets are still unexplored.
Cisek, Katryna, Delles, Christian, Filip, Szymon, Gakiopoulou, Chara, Jankowski, Joachim, Krochmal, Magdalena, Markoska, Katerina, Mischak, Harald, Orange, Clare, Spasovski, Goce, Vlahou, Antonia, Zoidakis, Jerome   +11 more
core   +2 more sources

A disintegrin and metalloproteinase domain 10 expression inhibition by the small molecules adenosine, cordycepin and N6, N6-dimethyladenosine and immune regulation in malignant cancers

Frontiers in Immunology
A disintegrin and metalloproteinase domain 10 (ADAM10), a member of the ADAM family, is a cellular surface protein with potential adhesion and protease/convertase functions.
Wenqian Zhang, Wenqian Zhang, Wenqian Zhang, Jiewen Fu, Jiaman Du, Xiaoyan Liu, Jingliang Cheng, Chunli Wei, Youhua Xu, Junjiang Fu, Junjiang Fu   +10 more
doaj   +1 more source

Structural and functional analyses of the shedding protease ADAM17 in HoxB8-Immortalized macrophages and dendritic-like cells [PDF]

, 2018
A disintegrin and metalloproteinase (ADAM) 17 has been implicated in many shedding processes. Major substrates of ADAM17 are TNF-α, IL-6R, and ligands of the epidermal growth factor receptor.
Arnold, Philipp, Boss, Melanie, Cabron, Anne-Sophie, Dobert, Jan Philipp, El azzouzi, Karim, Linder, Stefan, Pavlenko, Egor, Renné, Thomas, Rosas, Marcela, Rose-John, Stefan, Schumacher, Neele, Schwarz, Jeanette, Taylor, Philip R., Zunke, Friederike   +13 more
core   +2 more sources

ADAM10 and ADAM17: New Players in Trastuzumab Resistance

Oncotarget, 2014
The availability of the anti-HER2 monoclonal antibody, trastuzumab (Herceptin) has transformed the outcome of a subgroup of patients with breast cancer that previously had a poor prognosis, i.e., those with HER2-positive disease [1]. Although HER2 gene amplification/overexpression is necessary for breast cancer patients to receive trastuzumab, more ...
Michael J, Duffy, John, Crown, Maeve, Mullooly   +2 more
openaire   +2 more sources

Mechanism of synergistic enhancement of α-secretase (ADAM10) activity by EGCG and FA

ChemPhysMater
Enhancing the activity of α-secretase has emerged as a potential therapeutic strategy for treating Alzheimer's disease (AD). The exploration of small molecules that can enhance α-secretase activity and their mechanisms provides insights for future AD ...
Yvning Guan, Wen Xu, Hongqi Ai
doaj   +1 more source